Transcript PowerPoint-Präsentation
Universities Allied for Essential Medicines
Clara Matthiessen/Aaron Vogt *
Universities Allied for Essential Medicines (UAEM)
• International, interdisciplinary student organisation • Founded in 2001 at Yale University • USA, Canada, Germany, UK, Norway, Denmark, soon Switzerland • Access to Lifesaving Medicine *
Case studies
*
Canada
•
Patient with high blood pressure
•
Treatment possibilities > 50
•
Price 20 – 100 $ /yr
•
Easy Access / receive a prescription from your GP
•
Few Adverse Effects
*
Southeast Asia
Leishmaniasis (Kala Azar)
• • •
Treatment Possibilities: 5 Price : $50-500/ 20-30 days Adverse Effects:
•
Toxic
•
Gastrointestinale problems, fever, fatigue, change in BP, diabetes...
•
Access to the Treatment: rare
*
Medical Patent
Eflorithine
- Produced in 1980. - The only effective treatment against trypanosomiasis (African Sleeping Sickness). - Sanofi Aventis had the patent for Eflorithine.
*
1995:
No effect seen for cancer treatments with Eflorithine
Sanofi Aventis
- Stopped all production - Still had exclusive rights for Eflorithine for 5 more years *
2000:
Effect against unwished hairgrowth discovered
Sanofi Aventis
- started production of Vaniqa - Monopol for this Product
New patent for 20 years more!
*
The Problem
*
The Access Gap
Ten million people die needlessly each year because they do not have access to existing medicines and vaccines. *
The Research Gap
90% of research goes into only 10% of the global disease burden. There is no commercial interest in research on neglected diseases.
[Drugs for Neglected Disease initiative www.dndi.org] *
UAEM History and Mission
*
Our Mission
Access
promote access to medicines and medical innovations in low- and middle-income countries by changing norms and practices around academic patenting and licensing
Innovation
ensure that university medical research meets the needs of people worldwide
Empowerment
empower students to respond to the access and innovation crisis *
Our History
40 major research universities
– including Harvard, Yale and Charité in Berlin –
have committed to license globally relevant biomedical research openly in low- and middle income countries.
This equitable licensing approach enables producers to manufacture affordable versions of new university-discovered medicines for neglected populations.
In 2001, Yale medical and law students convinced the university and Bristol-Myers-Squibb to
reduce the price of Stavudine by 95%
in South Africa.
*
UAEMs work
*
The Role of Universities in Drug Development
•Every single vaccine brought to market in the past 25 years has a contribution from university research. [Ashley Stevens, current President of AUTM; Access to Medicines panel discussion, Yale University March 25, 2008] •More than 1/3 of HIV drugs introduced between 2002 and 2006 involve a university patent.
*
Our Work
•
Local and national campaigns at universities
•
University Administration /TTO
•
Political focus National, EU and WHO
•
Administration of chapters and working groups
*
We are not alone ...
*
”The right to life includes the right to health and access to treatment”
[
Articles 1&25, Universal Declaration of Human Rights, United Nations General Assembly 1948.]
*
A Chapter in Switzerland
www.essentialmedicine.org
andrea [email protected]
- Next German UAEM Meeting: 7th-9th of December in Münster - Next European UAEM Meeting: April 2013 in Copenhagen *